Keyphrases
Cancer Immunotherapy
100%
Antitumor Effect
100%
CD-8
100%
Cytotoxic T-lymphocyte antigen-4 (CTLA-4)
100%
CD8+ T Cells
66%
Interleukin-2
66%
T Cells
33%
Rational Design
33%
CD40
33%
Tumor Immunity
33%
Bystander
33%
Negative Regulator
33%
T Cell Activation
33%
Effector Memory
33%
T Cell Response
33%
Number of Factors
33%
Combination Immunotherapy
33%
Anti-CD40
33%
Immunomodulatory Therapy
33%
Tumor Subtype
33%
Synergistic Antitumor Effect
33%
Severe Toxicity
33%
Metastatic Site
33%
Anti-cytotoxic
33%
Anti-tumor Response
33%
Memory Phenotype
33%
Medicine and Dentistry
Neoplasm
100%
Cancer Immunotherapy
100%
CTLA-4
100%
CD8 Antigen
100%
T-Cell Response
40%
Cytotoxic T-Cell
40%
Interleukin 2
40%
T Cell
20%
T Cell Activation
20%
Tumor Immunity
20%
Immunotherapy
20%
Immunology and Microbiology
CD8
100%
CTLA-4
100%
Cancer Immunotherapy
100%
Cytotoxic T-Cell
66%
Interleukin 2
66%
T Cell
66%
T Cell Activation
33%
Tumor Immunity
33%
Immunotherapy
33%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
CD8 Antigen
100%
Neoplasm
100%
Immunotherapy
100%
Cytotoxic T Lymphocyte Antigen 4
100%
Interleukin 2
33%